Interchangeability can be employed by pharmacists to switch a reference product with a biosimilar. What are your best practices for employing this in your practice?

As a quirky feature of the U.S. market, not having a therapeutic interchangeability designation is considered an important impediment to physician and patient confidence in biosimilars.

Number 4: The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to ...